Little Green Pharma Ltd. · ASX:LGP
Little Green Pharma — Investor Presentation (October 2024)
17 slides from Little Green Pharma's investor presentation, Oct 28, 2024
Slide 1: Investor webinar invitation & presentation
ASX ANNOUNCEMENT 28 October 2024 Investor webinar invitation & presentation For personal use only Little Green Pharma Ltd (ASX: LGP, “LGP” or the “Company”) is pleased to provide investors with the following investor presentation, which will be presented as part of a webinar later today (details bel
Slide 2: About Little Green Pharma
ENDS BY ORDER OF THE BOARD __________________ Alistair Warren Company Secretary For further information please contact: Alistair Warren David Tasker Company Secretary Managing Director Little Green Pharma Chapter One Advisors E: a.warren@lgp.global E: dtasker@chapteroneadvisors.com.au For personal u
Slide 3: Investor presentation October 2024
September 2024 Quarterly & Appendix 4C ASX:LGP For personal use only Investor presentation OCTOBER 2024 The most trusted medicinal cannabis brand
Slide 4: Disclaimer
2 Disclaimer Disclaimer Not financial product advice For personal use only This presentation contains summary information about Little Green Pharma Ltd (ACN 615 586 215) (“LGP”) and its This document does not constitute financial product advice or take into account your investment objectives, activi
Slide 5: Little Green Pharma
Little Green Pharma For personal use only 30t 4 BRANDS 26 PRODUCTS 3 FACILITIES PRODUCTION CAPACITY 11 13 SPONSORED 94 STAFF ACROSS 20+ STRAINS DISTRIBUTION TERRITORIES STUDIES / TRIALS 5 COUNTRIES GENETICS BANK
Slide 6: Market update: from rationalisation to resurgence
MARKET UPDATE Market update For personal use only From rationalisation to resurgence Cannabis markets in US and Canada have been rationalising for several years due to oversupply and distorted markets Cannabis markets in Germany, France and UK are experiencing a resurgence, while Australia continues
Slide 7: Market opportunity
MARKET OPPORTUNITY Market opportunity For personal use only LGP’s global markets KEY Production facility and supplied market Supplied market Supply arrangements LGP holds a 6.5% stake in local producer LGP MARKETS 5
Slide 8: Revenue and cash receipts
REVENUE & CASH RECEIPTS Revenue and Revenue vs cash receipts ($000’s) cash receipts For personal use only 12,000 10,754 11,000 10,000 Record revenue of $10.2 8,209 10,152 9,000 million (unaudited), up 40% on prior quarter and nearly 8,000 6,605 60% on previous 7,000 corresponding quarter 7,307 6,000
Slide 9: Revenue by product category
REVENUE BY PRODUCT CATEGORY Revenue by product category ($000’s) 12,000 10,000 Revenue by 8,000 product category For personal use only 6,000 4,000 2,000 45% increase in oil sales driven by growth in both 0 FY24Q4 FY25Q1 FY25Q2 FY25Q3 FY25Q4 France and Australia Flower Oil Vaporiser Other Over 35% in
Slide 10: Revenue by segment
REVENUE BY SEGMENT Revenue by segment ($000’s) 12,000 10,000 Revenue by 8,000 segment For personal use only 6,000 4,000 2,000 Over 30% increase in flower sales in Australia - FY24Q4 FY25Q1 FY25Q2 FY25Q3 FY25Q4 coupled with a 35% Australia Europe increase in oil sales 60% increase in flower Revenue b
Slide 11: Revenue by brand
REVENUE BY BRAND Revenue by brand ($000’s) Revenue by brand 12,000 For personal use only 10,000 CherryCo sales up 50% on prior quarter despite a number of me-too products 8,000 appearing 6,000 LGP brand sales up nearly 30% on prior quarter including into France and 4,000 the UK 2,000 White label sal
Slide 12: EV, NTA, cash, debt and revenue
EV, NTA, CASH, DEBT AND REVENUE EV, NTA, cash, debt & annualised revenue ($000’s) EV, NTA, cash, debt and revenue For personal use only 100,000 100,000 80,000 80,000 Cash in bank of $4.8 million, up from $4.3 million 60,000 60,000 Minimal long-term debt 40,000 40,000 of $3.3 million Enterprise value
Slide 13: Comparable company analysis
Annual reporting review Comparable company analysis Analysis of where the top 20 cannabis operators from 20221 are now ($000’s) Ranking Company ASX Audited Financial Revenue YoY% Operating YoY% Net tangible YoY% Cash YoY% 20221 Statements cashflow assets For personal use only 1 Incannex Healthcare (
Slide 14: Comparable company analysis summary
ANNUAL REPORTING REVIEW Comparable company analysis For personal use only Summary LGP continues to outperform the majority of its competitors: Seven of original 20 cannabis peers from 2022 currently delisted or suspended from ASX Of remaining group: • LGP one of only two companies with positive oper
Slide 15: Corporate Overview
CORPORATE OVERVIEW Corporate Overview For personal use only Capital Structure Shareholder Structure Current Share Price1 $0.15 Shares Outstanding1 ~302 million Options and Performance Rights on Issue2 ~24.7 million 22% 29% Market Capitalisation (undiluted) ~$45.4 million Cash Reserves (30 September
Slide 16: Stars are aligning
INVESTMENT PROPOSITION Stars are aligning For personal use only Cannabis market size forecasts validated Biggest facility in Europe at low marginal cost Cashflow positive and record revenue Backed by hard assets Regulator crackdowns & competitor exits Slowing inflation and interest rates 14
Slide 17: Q&A
For personal use only Q&A Paul Long, CEO A world of difference investor.littlegreenpharma.com
Little Green Pharma — Investor Presentation (October 2024) on 6ix